Log in

IAM Iambic Therapeutics, Inc. NASDAQ · United States

Iambic Therapeutics (IAM) news IAM IPO and offering news

Latest Iambic Therapeutics news

  1. Financings

    Iambic Therapeutics files for IPO, plans Nasdaq listing as IAM

    Iambic Therapeutics, Inc. filed a Form S-1 on September 21, 2026. The cover leaves the share count and price range blank.

Questions about Iambic Therapeutics

When did Iambic Therapeutics go public?

Our latest story on this, dated Oct 15, 2026: "Iambic Therapeutics prices IPO of 9,375,000 shares at $16.00". The story links the filing or release it is based on. Read the story.

Has Iambic Therapeutics raised money recently?

Our latest story on this, dated Oct 15, 2026: "Iambic Therapeutics prices IPO of 9,375,000 shares at $16.00". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Iambic Therapeutics?

Iambic Therapeutics, Inc. trades under the ticker IAM on NASDAQ.

Where is Iambic Therapeutics listed?

Iambic Therapeutics, Inc. is listed on NASDAQ.

What is the SEC CIK of Iambic Therapeutics?

The SEC Central Index Key (CIK) for Iambic Therapeutics, Inc. is 1997038. Its filings are on SEC EDGAR.

Which country or territory is Iambic Therapeutics listed under?

Our directory records Iambic Therapeutics, Inc. under United States.

What does Iambic Therapeutics do?

Our directory classifies Iambic Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Iambic Therapeutics?

The ISIN recorded for Iambic Therapeutics, Inc. is US45076A1016.

Does aibio.space cover Iambic Therapeutics?

aibio.space lists Iambic Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Iambic Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

What is the latest Iambic Therapeutics (IAM) stock news?

Our latest story on Iambic Therapeutics, dated Oct 15, 2026: "Iambic Therapeutics prices IPO of 9,375,000 shares at $16.00". The offering totals $150,000,000 before fees. The stock has been approved for listing on the Nasdaq Global Select Market under the symbol IAM. Source.

Where is Iambic Therapeutics headquartered?

SEC records list its business address as 5627 OBERLIN DRIVE, SUITE 120, SAN DIEGO, CA, 92121.

When does Iambic Therapeutics's fiscal year end?

Iambic Therapeutics, Inc.'s fiscal year ends on December 31, per SEC records.

What did Iambic Therapeutics last file with the SEC?

Its most recent filing in our record is an 8-K filed 2026-10-16. All of its filings are on SEC EDGAR. Source.

What industry is Iambic Therapeutics in?

Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances).

Investor discussion: Iambic Therapeutics

Members talk about Iambic Therapeutics (IAM). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Iambic Therapeutics, newest first. Each line links the filing it comes from.

  1. Financings

    Filed a final prospectus for a securities offering. SEC Form 424B4. Source

  2. Financings

    Filed a registration statement for a share offering. SEC Form S-1. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:IAM on TradingView.

SEC filings and registration

SEC name
Iambic Therapeutics, Inc.
CIK
1997038
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
IAM (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Business address
5627 OBERLIN DRIVE, SUITE 120, SAN DIEGO, CA, 92121
Phone
(626) 592-2520

Recent filings (8-K and 6-K are the company's own announcements)

  • 8-K filed 2026-10-16
  • S-1 filed 2026-09-21

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Iambic Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IAM, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Iambic Therapeutics, Inc.
Ticker
IAM
Listing
NASDAQ
Country or territory
United States
Business scope
Biotechnology
ISIN
US45076A1016
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.